InvestorsObserver is giving Clarus Therapeutics Holdings Inc (CRXT) an Analyst Rating Rank of 69, meaning CRXT is ranked higher by analysts than 69% of stocks. The average price target for CRXT is $13.8 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating CRXT a Strong Buy today. Find out what this means to you and get the rest of the rankings on CRXT!